


## SUPPLEMENTARY INFORMATION

### Methylation patterns of the nasal epigenome of hospitalized SARS-CoV-2 positive patients reveals insight into molecular mechanisms of COVID-19


Benjamin L. Spector, Boryana Koseva, Rebecca McLennan, Dithi Banerjee, Kamani Lankachandra, Todd Bradley, Rangaraj Selvarangan, Elin Grundberg

#### Table of contents


Supplemental Figure 1: Hierarchical clustering of COVID-19 positive individuals shows no clustering by race or gender.	Page 2
Supplemental Figure 2	Page 3
Supplemental Figure 3: <i>ELF4</i> expressed broadly across immune cell types.	Page 4
Supplemental Figure 4: Distribution of <i>ELF4</i> transcription factor binding motifs across cell type-specific DHSs.	Page 5
Supplemental Table 1: Percent UMR and LMR overlapping regulatory elements by cell type in COVID-19 positive (severe + mild) and negative individuals	Page 6
Supplemental Table 2: Percent UMR and LMR overlapping regulatory elements by cell type in severe and mild COVID-19.	Page 7
Supplemental Table 3: Relatively hypomethylated genes in severe as compared to mild COVID-19 cases.	.XLSX
Supplemental Table 4: Relatively hypermethylated genes in severe as compared to mild COVID-19 cases.	.XLSX
Supplemental Table 5: Enriched pathways associated relatively hypomethylated genes in severe as compared to mild COVID-19 cases.	.XLSX
Supplemental Table 6: Enriched pathways associated relatively hypermethylated genes in severe as compared to mild COVID-19 cases.	.XLSX
Supplemental Table 7: PI3k/Akt pathway associated DMRs. Methylation difference reflects percent difference in mean regional methylation between hospitalized versus non-hospitalized COVID-19 subjects.	Page 8




**Supplemental Figure 1: Hierarchical clustering of COVID-19 positive individuals shows no clustering by race or gender.** Hierarchical clustering was performed at the top 25<sup>th</sup> percentile most variable CpG methylation sites and showed no clustering structure by race (Black individuals = Black, Caucasian individuals = Green, Other races = Red), or gender (Female = Black, Male = Red).



**Supplemental Figure 2:** CTL = Cytotoxic T lymphocytes, MC = Mast cell, moDC = Monocyte-derived dendritic cell, MoD-Ma = Monocyte-derived macrophage, Neu = Neutrophil, NK = Natural killer cell, NKT = NK T cell, NKT-p = Proliferating NKT cell, nrMA = non-resident macrophage, pDC = Plasmacytoid dendritic cell, rMA = Resident macrophage, Treg = Regulatory T cell. UMAP demonstrating differential gene expression by disease severity and cell-type in the nasopharynx. **(A)** Clustering by COVID-19 severity, Blue = Control, Red= Mild/moderate disease, Green = Critical disease. Gene expression as determined by scRNA-seq of **(B)** *TLR5*, **(C)** *MARK4*, **(D)** *ZEB2*, **(E)** *NOTCH1*, **(F)** *ITGB2*, **(G)** *IRF7*, **(H)** *NFKBIA*. Figure generated using the dataset of Chua *et al.* and the UCSC Cell Browser (<https://covid-airways.cells.ucsc.edu>) [45,47].



**Supplemental Figure 3: *ELF4* expressed broadly across immune cell types.** Presented as normalized transcripts per million (y-axis). Granulocytes = pink, Monocytes = red, T-cells = blue, B-cells = purple, Dendritic cells = teal, NK cells = magenta, Progenitors = olive, Total PBMC = brown. Figure generated using dataset of Monaco *et al.* Image credit: Human Protein Atlas. Image available from: [v23.proteinatlas.org/ENSG00000102034-ELF4/immune+cell](https://v23.proteinatlas.org/ENSG00000102034-ELF4/immune+cell)



**Supplemental Figure 4: Distribution of *ELF4* transcription factor binding motifs across cell type-specific DHSs.** Among hypermethylated regions, a higher percentage of *ELF4* transcription factor binding motifs (blue) localize to myeloid specific DHSs as compared to hypermethylated DMRs that are not targets of the *ELF4* transcription factor (orange).

**Supplemental Table 1:** Percent UMR and LMR overlapping regulatory elements by cell type in COVID-19 positive (severe + mild) and negative individuals.

Cell Type	Overlapping single or multiple cell types				Overlapping single cell type only			
	COVID-19 Status		<sup>a</sup> Fold Difference	<sup>b</sup> <i>p</i>	COVID-19 Status		<sup>a</sup> Fold Difference	<sup>b</sup> <i>p</i>
	Positive (%)	Negative (%)			Positive (%)	Negative (%)		
Immune								
UMR	64	62	1.0	0.0054	8	4	1.9	0.069
LMR	46	25	1.9	< 2.2 x 10 <sup>-16</sup>	31	8	4.1	0.0037
Lymphoid								
UMR	49	48	1.0	0.051	5	3	1.8	0.21
LMR	24	15	1.6	< 2.2 x 10 <sup>-16</sup>	11	4	2.6	5.6 x 10 <sup>-16</sup>
Myeloid								
UMR	33	32	1.0	0.0015	3	1	2.5	0.26
LMR	28	12	2.4	< 2.2 x 10 <sup>-16</sup>	20	3	6.3	< 2.2 x 10 <sup>-16</sup>
Pulmonary								
UMR	15	17	0.91	7.0 x 10 <sup>-5</sup>	0.6	0.7	0.83	1.0
LMR	7	10	0.66	< 2.2 x 10 <sup>-16</sup>	2	3	0.27	< 2.2 x 10 <sup>-16</sup>
Epithelial								
UMR	13	17	0.76	< 2.2 x 10 <sup>-16</sup>	0.6	3	0.18	0.032
LMR	8	19	0.43	< 2.2 x 10 <sup>-16</sup>	3	11	0.22	< 2.2 x 10 <sup>-16</sup>

<sup>a</sup>Fold difference between COVID-19 positive vs negative patients

<sup>b</sup>*p*-value reflects chi-square examining COVID-19 positive vs negative patients

**Supplemental Table 2:** Percent UMR and LMR overlapping regulatory elements by cell type in severe and mild COVID-19.

Cell Type	Overlapping single or multiple cell types				Overlapping single cell type only			
	COVID-19 Status		<sup>a</sup> Fold Difference	<sup>b</sup> <i>p</i>	COVID-19 Status		<sup>a</sup> Fold Difference	<sup>b</sup> <i>p</i>
	Severe (%)	Mild (%)			Severe (%)	Mild (%)		
Immune								
UMR	64	64	1.0	0.84	9	9	1.1	0.87
LMR	44	46	0.97	2.5 x 10 <sup>-6</sup>	28	31	0.90	9.3 x 10 <sup>-8</sup>
Lymphoid								
UMR	49	49	1.0	0.86	6	6	1.1	0.89
LMR	24	24	1.0	0.74	10	11	0.96	0.25
Myeloid								
UMR	34	33	1.0	0.55	3	3	1.0	1.0
LMR	26	28	0.94	1.8 x 10 <sup>-9</sup>	18	20	0.87	1.1 x 10 <sup>-7</sup>
Pulmonary								
UMR	15	15	1.0	0.89	0.3	0.3	0.95	1.0
LMR	7	7	0.99	0.59	1	2	0.93	0.50
Epithelial								
UMR	13	13	1.0	0.45	2	0.6	2.8	0.32
LMR	9	8	1.1	4.8 x 10 <sup>-8</sup>	4	3	1.4	5.1 x 10 <sup>-6</sup>

<sup>a</sup>Fold difference between severe vs mild COVID-19 patients

<sup>b</sup>*p*-value reflects chi-square examining severe vs mild COVID-19 patients

**Supplemental Table 7:** PI3k/Akt pathway associated DMRs. Methylation difference reflects percent difference in mean regional methylation between hospitalized versus non-hospitalized COVID-19 subjects.

Gene	Chromosome	Start	Stop	Methylation difference (%)	q-value
<i>AKT1</i>	chr14	104796001	104796500	-18.38	$2.22 \times 10^{-22}$
<i>ISG15</i>	chr1	1013751	1014250	-32.27	$2.49 \times 10^{-35}$
<i>ZEB2</i>	chr2	144524251	144524750	-24.39	$2.52 \times 10^{-32}$
<i>SNAI1</i>	chr20	49983251	49983750	-28.98	$6.11 \times 10^{-16}$
<i>TLR5</i>	chr1	223133001	223133750	-15.09	$1.22 \times 10^{-16}$
<i>MARK4</i>	chr19	45248251	45248750	-10.08	$2.33 \times 10^{-19}$
<i>NOTCH1</i>	chr9	136549501	136550000	-20.24	$2.23 \times 10^{-16}$
<i>ITGB2</i>	chr21	44923751	44924500	-22.09	$1.08 \times 10^{-33}$
<i>IRF7</i>	chr11	615001	615500	-17.76	$1.43 \times 10^{-33}$
<i>NFKBIA</i>	chr14	35402001	35402500	-15.80	$1.02 \times 10^{-16}$